Milwaukee Bucks star Giannis Antetokounmpo appeared to boo his own fans during his team’s 139-106 defeat to the Minnesota ...

Secretary of Defense Pete Hegseth, who is taking a tour of U.S. defense contractors, on Friday visited a Long Beach rocket maker, where he told workers they ...

Tourmaline went public in 2023 via a reverse merger with the struggling cell therapy developer Talaris. The deal gave Tourmaline funds to develop pacibekitug, an antibody that targets interleukin-6, a ...

A housing lottery has launched for 120 mixed-income apartments at a new rental in East Williamsburg. Rents start at $812 per ...

Pfizer developed a lab-made ingredient that is now found in roughly 90 percent of American cheese, and it does not have to be ...

Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...

I was taken aback to hear the government had selected GC Biopharma as a company to support in phase 1 (first-stage clinical trials) for an mRNA COVID-19 vaccine. Phase 1 again?… How many times have we ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth, despite management's guidance and cost-cutting efforts. Recurring unusual ...

Pfizer stock has been a weak performer, declining by about 7% through 2025. Things could remain mixed over 2026 as well, with the company guiding for revenues of $59.5-$62.5 billion and adjusted EPS ...

Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...